AIGH Capital Management LLC Cuts Stake in Coya Therapeutics, Inc. $COYA

AIGH Capital Management LLC cut its holdings in shares of Coya Therapeutics, Inc. (NASDAQ:COYA) by 6.6% in the 2nd quarter, Holdings Channel reports. The fund owned 1,105,622 shares of the company’s stock after selling 78,158 shares during the period. Coya Therapeutics accounts for about 2.9% of AIGH Capital Management LLC’s investment portfolio, making the stock its 16th biggest position. AIGH Capital Management LLC owned 0.07% of Coya Therapeutics worth $6,357,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. CM Management LLC grew its stake in shares of Coya Therapeutics by 25.0% during the first quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $1,294,000 after acquiring an additional 40,000 shares in the last quarter. Dauntless Investment Group LLC acquired a new stake in shares of Coya Therapeutics during the first quarter valued at about $1,083,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Coya Therapeutics during the first quarter valued at about $65,000. Finally, Jane Street Group LLC grew its stake in shares of Coya Therapeutics by 101.7% during the first quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock valued at $169,000 after acquiring an additional 13,176 shares in the last quarter. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Coya Therapeutics Stock Performance

NASDAQ:COYA opened at $6.36 on Monday. The company has a market capitalization of $106.40 million, a price-to-earnings ratio of -5.13 and a beta of 0.19. Coya Therapeutics, Inc. has a one year low of $4.65 and a one year high of $10.24. The stock has a 50-day simple moving average of $6.14 and a 200 day simple moving average of $5.96.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Tuesday, August 12th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.14). The business had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.78 million. On average, equities research analysts forecast that Coya Therapeutics, Inc. will post -1.15 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Lake Street Capital assumed coverage on Coya Therapeutics in a research note on Wednesday, July 9th. They set a “buy” rating and a $16.00 target price for the company. BTIG Research restated a “buy” rating and set a $15.00 target price on shares of Coya Therapeutics in a research note on Tuesday, September 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, October 8th. D. Boral Capital reiterated a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a research note on Monday, September 29th. Finally, HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a research note on Monday, August 25th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $16.20.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.